LOM
ABUS icon

Loeb Offshore Management’s Arbutus Biopharma ABUS Stock Holding History

Loeb Offshore Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,000
Closed -$70K – 189
2013
Q3 		$70K Buy
+10,000
New +$55.1K 0.02% 212

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IGIM
I.G. Investment Management Winnipeg, Manitoba, Canada $19.5B AUM 15.95% 1-Year Est. Return

Loeb Offshore Management's ABUS Position: Q4 2013 in Review

Loeb Offshore Management sold out of Arbutus Biopharma (ABUS) in Q4 2013, closing a stake of 10,000 shares — an estimated $70K sold.

Loeb Offshore Management first reported a position in ABUS in Q3 2013 and held it in 1 quarter. The position peaked at $70K in Q3 2013. 24 funds tracked by Wall St. Rank hold ABUS as of Q4 2013.

  • Loeb Offshore Management reported no remaining Arbutus Biopharma position as of Q4 2013 after selling out during the quarter.
  • Loeb Offshore Management sold 10,000 Arbutus Biopharma shares in Q4 2013, an estimated $70K.
  • Loeb Offshore Management first reported a position in Arbutus Biopharma in Q3 2013 and held it in 1 quarter.
  • Loeb Offshore Management's Arbutus Biopharma position peaked at $70K in Q3 2013.
  • 24 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2013.

Based on Loeb Offshore Management's 13F filing for Q4 2013, filed 14 Feb 2014.